Data RequirementsMore data, including more patients, multiple doses, and longer follow-up, will be needed to properly characterize any potential differences in safety profile between briquilimab and barzolvolimab.
Investor SentimentShort Interest is at 12.7% of the float, which may indicate a level of pessimism among some investors.
Treatment EfficacyBriq's durability appears suboptimal with the current doses, as responses seemed to wane with only 6 complete responses and 1 partial response at day 43.